Article Versions Notes

Anastay V, Baboudjian M, Masson-Lecomte A, Lebacle C, Chamouni A, Irani J, Tillou X, Waeckel T, Monges A, Duperron C, et al. Is CIS a Contraindication to Hyperthermic Intravesical Chemotherapy (HIVEC) after BCG-Failure? Cancers. 2023; 15(5):1455. https://doi.org/10.3390/cancers15051455

Anastay, Vassili, Michael Baboudjian, Alexandra Masson-Lecomte, Cédric Lebacle, Alexandre Chamouni, Jacques Irani, Xavier Tillou, Thibaut Waeckel, Arnaud Monges, Céline Duperron, and et al. 2023. "Is CIS a Contraindication to Hyperthermic Intravesical Chemotherapy (HIVEC) after BCG-Failure?" Cancers 15, no. 5: 1455. https://doi.org/10.3390/cancers15051455

Anastay, V., Baboudjian, M., Masson-Lecomte, A., Lebacle, C., Chamouni, A., Irani, J., Tillou, X., Waeckel, T., Monges, A., Duperron, C., Gravis, G., Walz, J., Lechevallier, E., & Pignot, G. (2023). Is CIS a Contraindication to Hyperthermic Intravesical Chemotherapy (HIVEC) after BCG-Failure? Cancers, 15(5), 1455. https://doi.org/10.3390/cancers15051455